Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors from France-based Innate Pharma (NASDAQ: IPHA), as per an agreement reached in 2022. Sanofi will pay an initial fee of EUR 15 million (USD 16.4 million) and is committed to potential milestone payments of up to EUR 1.35 billion, plus royalties. The agreement also grants Sanofi an option to an additional poly-specific antibody-based engager.
The collaboration between Sanofi and Innate dates back to 2016, with Sanofi previously acquiring development, manufacturing, and commercialization rights to several trifunctional molecules, including anti-CD123 NKp46xCD16 (Phase I), anti-BCMA NKp46xCD16 (Phase I), and anti-B7-H3 NKp46xCD16 (preclinical), as well as an undisclosed candidate.
Innate Pharma’s roster of collaborators includes major pharmaceutical companies such as AstraZeneca (AZ, NASDAQ: AZN), Bristol Myers Squibb (BMS, NYSE: BMY), and Novo Nordisk (CPH: NOVO-B).- Flcube.com
